1st line Relapsed or Metastatic mucosal, HNSCC, not NPC

**Treatment**

**HPV(+)**
- Prior ICI Injectible lesions
  - HLA Matched PDL1(+)
    - ENT0072 Phase I CUE-101 Monotherapy in HPV+ Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma (HNSCC)
      - PI: Colevas Cue Biopharma
    - PDL1(+)
    - PDL1(-)
  - PDL1(+)
    - ENT0084 Phase II Study of Ipilimumab in Combination with Pembrolizumab for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
      - PI: Colevas BioNTech SE
  - PDL1(-)

**HPV(-)**
- Any PDL1
  - ENT0088 Phase II Nivolumab Combination Therapy in Head and Neck Squamous Cell Carcinoma
    - PI: Colevas Gilead Sciences, Inc.
  - PDL1(+)
    - ENT0097 A Phase II Study of Ipilimumab in Combination with Pembrolizumab for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
      - PI: Colevas PNP Therapeutics
    - ENT0064 Phase 1b Ad/PNP-F-araAMP + Co-Admin of Fludarabine Phosphate in Recurrent Local Head & Neck Cancer
      - PI: Colevas Gilead Sciences, Inc.